# MBX: Advancing late-stage peptide therapies with pivotal data and new obesity candidates expected by 2027 - TradingView

*Источник: TradingView*
*Дата: 2026-09-16*
*Язык: en*

**Кратко:** MBX: Advancing late-stage peptide therapies with pivotal data and new obesity candidates expected by 2027
Leadership is focused on advancing canvuparatide to full phase III enrollment and preparing for commercialization, while MBX 4291 targets once-monthly obesity treatment with key data expected in Q4. The platform supports a robust pipeline, with two new obesity candidates aiming for INDs by 2027.

MBX: Advancing late-stage peptide therapies with pivotal data and new obesity candidates expected by 2027
Leadership is focused on advancing canvuparatide to full phase III enrollment and preparing for commercialization, while MBX 4291 targets once-monthly obesity treatment with key data expected in Q4. The platform supports a robust pipeline, with two new obesity candidates aiming for INDs by 2027.

[Оригинал](https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4175572:0-mbx-advancing-late-stage-peptide-therapies-with-pivotal-data-and-new-obesity-candidates-expected-by-2027/)